Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Tabrizi SJ., Reilmann R., Roos RAC., Durr A., Leavitt B., Owen G., Jones R., Johnson H., Craufurd D., Hicks SL., Kennard C., Landwehrmeyer B., Stout JC., Borowsky B., Scahill RI., Frost C., Langbehn DR.